• +1-646-491-9876
    • +91-20-67278686

    Search

    Community Acquired Pneumonia Pipeline Review H2 2017

    Community Acquired Pneumonia Pipeline Review H2 2017

    • Report Code ID: RW0001884152
    • Category Pharmaceuticals
    • No. of Pages 106
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Community Acquired Pneumonia - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2017, provides an overview of the Community Acquired Pneumonia (Infectious Disease) pipeline landscape.

    Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside a hospital or long-term care facility. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Pneumonia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Community Acquired Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3, 6, 2, 1 and 1 respectively.

    Community Acquired Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Community Acquired Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Community Acquired Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Community Acquired Pneumonia (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Community Acquired Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Community Acquired Pneumonia - Overview
    Community Acquired Pneumonia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Community Acquired Pneumonia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Community Acquired Pneumonia - Companies Involved in Therapeutics Development
    Aridis Pharmaceuticals LLC
    Biotest AG
    InflaRx GmbH
    ioGenetics Inc
    Kyorin Pharmaceutical Co Ltd
    Melinta Therapeutics Inc
    Merck & Co Inc
    Nabriva Therapeutics AG
    Paratek Pharmaceuticals Inc
    TaiGen Biotechnology Co Ltd
    Takeda Pharmaceutical Company Ltd
    Tetraphase Pharmaceuticals Inc
    TiGenix NV
    Wockhardt Ltd
    Community Acquired Pneumonia - Drug Profiles
    BT-086 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CAL-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ceftaroline fosamil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cx-611 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DBAF-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    delafloxacin meglumine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IFX-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lascufloxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lefamulin acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nafithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nemonoxacin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omadacycline tosylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PneumoMab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    solithromycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tosatoxumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-271 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Community Acquired Pneumonia - Dormant Projects
    Community Acquired Pneumonia - Discontinued Products
    Community Acquired Pneumonia - Product Development Milestones
    Featured News & Press Releases
    Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
    Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin
    Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
    May 30, 2017: TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn Intravenous Formulation to the China Food and Drug Administration
    Apr 25, 2017: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic Data
    Apr 21, 2017: Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups
    Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
    Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
    Apr 03, 2017: Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
    Mar 28, 2017: Cempra Withdraws Solithromycin Marketing Authorization Application in Europe
    Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
    Jan 18, 2017: Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
    Dec 29, 2016: Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
    Dec 20, 2016: Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia
    Dec 13, 2016: Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Community Acquired Pneumonia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
    Community Acquired Pneumonia - Pipeline by Biotest AG, H2 2017
    Community Acquired Pneumonia - Pipeline by InflaRx GmbH, H2 2017
    Community Acquired Pneumonia - Pipeline by ioGenetics Inc, H2 2017
    Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
    Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc, H2 2017
    Community Acquired Pneumonia - Pipeline by Merck & Co Inc, H2 2017
    Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H2 2017
    Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc, H2 2017
    Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
    Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
    Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
    Community Acquired Pneumonia - Pipeline by TiGenix NV, H2 2017
    Community Acquired Pneumonia - Pipeline by Wockhardt Ltd, H2 2017
    Community Acquired Pneumonia - Dormant Projects, H2 2017
    Community Acquired Pneumonia - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Community Acquired Pneumonia, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Targets, H2 2017
    Number of Products by Stage and Targets, H2 2017
    Number of Products by Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Aridis Pharmaceuticals LLC
    Biotest AG
    InflaRx GmbH
    ioGenetics Inc
    Kyorin Pharmaceutical Co Ltd
    Melinta Therapeutics Inc
    Merck & Co Inc
    Nabriva Therapeutics AG
    Paratek Pharmaceuticals Inc
    TaiGen Biotechnology Co Ltd
    Takeda Pharmaceutical Company Ltd
    Tetraphase Pharmaceuticals Inc
    TiGenix NV
    Wockhardt Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//community-acquired-pneumonia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//community-acquired-pneumonia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//community-acquired-pneumonia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments